According to , recently published report ‘Psoriasis – Pipeline Review, H2 2016’; Psoriasis pipeline therapeutics constitutes close to 264 molecules. Out of which approximately 247 molecules are developed by Companies and remaining by the Universities/Institutes.
Request for sample @ https://marketreportscenter.com/request-sample/438520
Furthermore, research says; Psoriasis Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.
Check Discount on report @ https://marketreportscenter.com/request-discount/438520
The report ‘Psoriasis – Pipeline Review, H2 2016’ outlays comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 39, 29, 2, 96, 37 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 7 molecules, respectively.
For more details of report, table of content, purchase copy of report visit https://marketreportscenter.com/reports/438520/psoriasis-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center